---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-000916"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-07-26T23:59:59+00:00"
generated_at: "2026-06-30T02:45:14.468117+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend

## Summary
- Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.
- Raises full-year revenue and earnings guidance; initiates Q3 guidance.
- Agrees to acquire BioLegend, a leading antibody & research reagent provider.
- GAAP operating margin 27.1% (vs 21.6% Q2 2020); adjusted margin 33.5% (vs 28.1%).
- Earnings call moved to July 26 at 8:00 a.m. ET.

## SEC filing metadata
- accession: 0001157523-21-000916
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-07-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/0001157523-21-000916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/a52464567.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-000916
- JSON: https://secwatch.observer/filing/0001157523-21-000916.json
- Plain text: https://secwatch.observer/filing/0001157523-21-000916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.